Redsense signs distribution agreement for Spain with Palex Medical
Redsense Medical has signed a distribution agreement for Spain with the company Palex Medical.
A first order for the company’s blood loss alarm is expected in the coming weeks so that the system can be evaluated with Spanish health care professionals. The company also holds the distribution rights for directly compatible hemodialysis machines from Redsense’s collaboration partner Nikkiso.
Spain is one of the largest hemodialysis markets in Europe with approximately 24 000 patients. Palex Medical is mainly focused on the public health care actors that covers around 40 percent or close to 10 000 of these patients.
“With this agreement, Redsense now has a strong distribution partner on the important Spanish market, which is positive for our European presence. We look forward to contributing to better patient safety for hemodialysis patients in Spain, thus lowering the cost of care,” says Patrik Byhmer, CEO of Redsense Medical.
Palex Medical was founded over 60 years ago, and has approximately 300 employees offering a broad range of medical products in Spain. The company has a close relationship with public health care actors and strives to identify and offer innovative medical products and solutions as they become available.
For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 29th of December 2017.